Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis: an Open-label, Non-inferiority, Randomised Clinical Trial

Uveitis and its complications are thought to account for 10 to 15% of preventable blindness in Western countries. The diagnosis of chronic non-infectious uveitis (CNUI) can be made after exclusion of pseudo uveitis or infectious uveitis, in the case of any persistent uveitis or uveitis with frequent relapses occurring less than 3 months after cessation of treatment. Adalimumab (ADA), an anti-TNFα monoclonal antibody, has marketing authorization and is widely used in the treatment of UCNI as a relay to corticosteroids. The use of ADA has been optimized, in particular through Therapeutic Drug Monitoring (TDM), based on the determination of serum ADA levels and anti-ADA antibodies. Recently, an article showed that a strategy of spacing ADA administrations in RA patients with concentrations >8 μg/mL was not inferior to standard.

Start Date01 Mar 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Saint-Etienne

NCT02586831 / WithdrawnPhase 1/2IIT

A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes

To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects receiving combinational therapy versus those receiving placebo. The study will also examine the effect of the proposed treatments on immunological outcomes, specifically proportion of regulatory T cells at the 1 year visit.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Miami

[+1]

NCT06729463 / RecruitingNot ApplicableIIT

IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients and Its Relation With Response to Systemic Biologic Therapy

Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients' quality of life enormously.
Psoriasis refers to a persistent inflammatory illness of the skin and joints. It also impacts roughly 2%-3% of the inhabitants of the universe

Start Date01 Dec 2024

Sponsor / Collaborator

South Valley University

100 Clinical Results associated with Adalimumab

100 Translational Medicine associated with Adalimumab

100 Patents (Medical) associated with Adalimumab

9,264

Literatures (Medical) associated with Adalimumab

01 Feb 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Predictors of Therapy Success in Weekly Adalimumab for Refractory Uveitis: A Retrospective Cohort Study

Article

Author: Janetos, Timothy M ; Goldstein, Debra A ; Kanwar, Kunal ; Bashey, Saffiya ; Koreishi, Anjum

PURPOSE:

To determine predictors of treatment success after dose escalation of adalimumab, including the measurement of anti-adalimumab antibodies as a predictor of success.

DESIGN:

Retrospective clinical cohort study.

METHODS:

Setting: Single-center academic institution.

STUDY POPULATION:

Patients with noninfectious uveitis who were inadequately controlled or developed recurrent disease on every other week adalimumab and required dose escalation or therapy modification.

OBSERVATION PROCEDURES:

Patients who had anti-adalimumab antibodies checked with resultant low to intermediate levels were compared with patients who had no testing performed before adalimumab dose escalation. Of note, patients with testing and resultant high levels of anti-adalimumab antibodies were not escalated. Predictors of escalation success and utility of antibody testing before escalation were analyzed using Kaplan-Meier survival analysis and Cox proportional hazards models.

MAIN OUTCOME MEASURES:

Treatment success defined as anterior chamber grade ≤0.5+ cell, topical corticosteroids ≤1 drop/d, oral prednisone ≤5 mg/d, resolution of macular edema, and resolution of angiographic signs of inflammation without any addition or escalation of therapy.

RESULTS:

A total of 24 patients had antibodies tested with low to intermediate levels (average: 32.3 ng/mL, range: 0-154 ng/mL), whereas 41 did not have antibody testing. A greater treatment success rate after escalation was observed among the "low antibody" group compared with the "no testing" group (hazard ratio: 2.63, standard error: 1.19, P = .031, 95% CI: 1.09-6.37). Among the entire cohort, patients with panuveitis (n = 14) had a lower treatment success rate compared with the reference of anterior uveitis (n = 26) (hazard ratio: 0.09, standard error: 0.11, P = .05, 95% CI: 0.01-0.99).

CONCLUSIONS:

Patients with low anti-adalimumab antibodies had a greater treatment success than patients in whom antibodies were not checked. This suggests a utility to checking antibodies before dose escalation and that low levels of antibodies may confer a success advantage. Overall, patients with panuveitis had a lower rate of success after escalation while patients with anterior uveitis patients had a very high rate of success suggesting that certain disease characteristics may guide clinicians when determining who to escalate versus changing therapy.

01 Feb 2025·JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Peri-implantation treatment with TNF-α inhibitor for endometriosis and/or adenomyosis women undergoing frozen-thawed embryo transfer: A retrospective cohort study

Article

Author: Yin, Ping ; Yuan, Yuan ; Li, Yan ; Liu, Mengqi ; Jiang, Min ; Yang, Dongzi

PROBLEM:

Endometriosis and adenomyosis have common pathogenesis and close relationship, with multi-factors involved in related infertility and IVF failure. They lead to anatomical changes, ovarian reserve reduction, endocrine abnormalities, altered endometrial receptivity and immunological dysfunction. Collective evidence indicate that abnormal function of immune cells and secretion of cytokines are closely related to reproductive outcomes among the women. Some studies showed that increased secretion of tumor necrosis factor alpha (TNF-α) led a key role in pro-inflammatory response in women with endometriosis/adenomyosis.TNF-a is embrryotoxic and receptivity impairing. Therefore, immunotherapy is a targeted therapeutic strategy apart from routine treatment. TNF-α inhibitors such as etanercept and adalimumab were shown to reduce the embryotoxic and anti-inflammatory effects to increase IVF pregnancy rates in recurrent implantation failure or endometrioma patient. However, there's no evidence about the use of adalimumab for patients with endometriosis and/or adenomyosis undergoing Frozen embryo transfer(FET).

METHOD OF STUDY:

A retrospective analysis of 141 women with endometriosis and/or adenomyosis undergoing FET from January 2021 to Jun 2023 was conducted.They were 20-42 years old, with or without previous implantation failure. Endometriosis was diagnosed by laparoscopy during their infertility workup and adenomyosis was confirmed by vaginal ultrasound screening. GnRH agonist and hormone replacement treatment (HRT) or HRT were taken for endometrium preparation according to doctor's evaluation and preference. Before and after embryo transfer, 84 women were treated with Adalimumab and 57 patients were untreated. Implantation rate, clinical pregnancy rate, ongoing pregnancy rate and live birth rate were compared between the two groups.

RESULTS:

The demographics and baseline characteristics between the two groups were comparable. Stage of embryo transferred and number of embryo transferred were comparable between the two groups (p = 0.227 and p = 0.204 separately). The regimen of endometrium preparation was similar too(p = 0.907). The implantation rate was significantly improved in study group (28.09 % vs 49.18 %, X²=9.515, P = 0.002). The clinical pregnancy rate was much lower in control group comparing with TNF-α inhibitor treatment group (42.11 % vs 60.71 %, X²=4.723, P = 0.029). There was no significant difference between the two groups as for ongoing pregnancy rate (38.60 % vs 52.38 %, X²=2.591, P = 0.107)and live birth rate (36.84 % vs 47.62 %, X²=1.606, P = 0.205). Following adjustment for age, BMI, number of prior failed transfer, stage of embryo transferred in a multiple logistic analysis, patients treated without TNF-α inhibitor had a significant lower CPR (ORadj 0.45, 95 %CI 0.22-0.92, p = 0.029) and a similar probability for OPR (ORadj 0.56, 95 %CI 0.28-1.12) and LBR (ORadj 0.62, 95 %CI 0.31-1.26) as compared with patients with TNF-α inhibitor treatment. However, an obvious trend of improvement of LBR was observed and it's clinical relevant for the patients.

CONCLUSION:

In women with endometriosis and/or adenomyosis, peri-implantation treatment with TNF-α inhibitor increased implantation rate and clinical pregnancy rate significantly compared with control group in FET cycles. The ongoing pregnancy rate and live birth rate were not significant different, while the difference was clinical relevant.

01 Jan 2025·Methods in molecular biology (Clifton, N.J.)

Codon and Signal Peptide Optimization to Enhance Therapeutic Antibody Production from CHO Cells

Article

Author: Oli, Deepesh ; Srila, Witsanu ; Yamabhai, Montarop

A simple and rapid method for reproducible transient expression experiments to quickly identify the best conditions before the development of a stable CHO cell line is described, using adalimumab as a model antibody. Firstly, the signal peptide (SP) is optimized using different in silico programs, of which those having a D score of more than 0.85 will be selected. A list of useful SPs is provided. Next, guidelines for selecting the codon optimization algorithm is provided based on a CAI value of more than 0.95. After that, the codon optimized genes of the heavy chain (HC) and light chain (LC) of an antibody with different SPs are engineered into an expression vector and the two recombinant plasmids are co-transfected into a CHO cell line of interest. The antibody titer, specific productivity (Qp), and viable cell density (VCD) are then checked by ELISA and flow cytometry analysis. The best SP pairs can then be used for the development of stable CHO cell lines.

1,000

News (Medical) associated with Adalimumab

23 Dec 2024

·www.globenewswire.com

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes REYKJAVIK, Iceland, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI). The addition comes as a part of the annual reconstitution of the index. Alvotech’s inclusion in the NBI will be effective when the U.S. market opens on Monday, December 23, 2024. The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet various eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. Nasdaq selects new constituents of the NBI once annually, in December. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube. Alvotech Forward Looking StatementsCertain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “aim” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to maintain criteria for inclusion in stock market indexes; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech’s estimates of expenses and profitability; (6) Alvotech’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company’s business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONSBenedikt Stefansson, VPalvotech.ir@alvotech.com

Biosimilar

19 Dec 2024

·www.businesswire.com

Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases

WALTHAM, Mass. & SHANGHAI--( BUSINESS WIRE )--Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize Palleon’s first-in-class human sialidase enzyme therapeutic, E-602, in combination with Henlius’ self-developed HANLIKANG (rituximab) in patients with autoimmune diseases, including lupus nephritis (LN). Depleting B cells with targeted antibodies such as rituximab (anti-CD20 mAb) is an established treatment for several autoimmune diseases, however, many patients have inadequate response to these drugs. Glyco-immunology provides a new approach to treating autoimmunity by enhancing depletion of activated memory B cells, the pathogenic subset of B cells associated with disease progression and often resistant to antibody-mediated depletion. E-602 enzymatically degrades sialoglycans—immunosuppressive cell surface sugars that protect pathogenic memory B cells from depletion by B cell-targeted antibodies. Preclinical studies of E-602 in combination with rituximab demonstrate improved outcomes versus rituximab alone without the risk of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) associated with CAR T and T cell engagers. E-602 has demonstrated a favorable safety profile with no dose-limiting toxicities in human clinical trials, which makes it suitable for the outpatient community setting. “Palleon’s glycan editing therapeutic has the potential to significantly improve treatment outcomes in patients who have autoimmune diseases including lupus nephritis, with a therapy that achieves optimal patient accessibility, including delivery in community outpatient settings,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “We look forward to continuing our successful partnership with Henlius and expanding glyco-immunology drug development to address a new category of patients in need of better treatment options.” Under the terms of the agreement, Henlius received an exclusive China license to Palleon’s E-602. Palleon is eligible to receive up to $95.3 million in certain predetermined development and commercial milestones, in addition to royalties upon E-602 commercialization in China. Henlius shall perform and fund E-602 development in China in combination with HANLIKANG for the treatment of lupus nephritis. This partnership expands upon Palleon and Henlius’ ongoing collaboration in oncology formed in June 2022 to co-develop targeted sialidase therapies in cancer. “We are pleased to expand our collaboration with Palleon Pharmaceuticals, the leader in the novel field of glyco-immunology,” said Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius. “HANLIKANG is the only rituximab approved for an autoimmune indication in China. We are committed to bringing better therapies to patients who suffer from lupus nephritis and other autoimmune conditions for which current treatment options are not always sufficient.” E-602 is a first-in-class human sialidase enzyme therapeutic developed from Palleon’s EAGLE glycan editing platform. HANLIKANG (rituximab) is the first-ever biosimilar developed and approved in China. About Palleon Pharmaceuticals Palleon Pharmaceuticals is the leading biotechnology company developing drugs that harness glyco-immunology to treat cancer and autoimmune diseases. The company’s proprietary platforms enable new target discovery, patient selection, and the development of novel therapeutics for devastating diseases characterized by immune system dysfunction. The groundbreaking discoveries of Palleon Co-Founder and Nobel laureate Carolyn Bertozzi enabled development of the company’s glycan editing therapeutic platform. www.palleonpharma.com About Henlius Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. To date, 6 products have been launched in China, 3 have been approved for marketing in overseas markets, 25 indications are approved worldwide, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. Henlius has established a global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP. Henlius has proactively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac ® in Europe), a China-developed mAb biosimilar approved in China, Europe and the U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab) and HANNAIJIA (neratinib), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors, squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer (nsNSCLC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.

License out/inImmunotherapyDrug Approval

17 Dec 2024

·endpts.com

Major PBM reforms feature in Congress' year-end spending bill

An end-of-year spending bill will include major reforms to the ways pharmacy benefit managers operate, including significant new restrictions on the fees and rebates that have huge influence over the cost of drugs and what products are covered. Congress has until Friday to pass the bill, known as the continuing resolution, which would fund government operations until mid-March and has become a vehicle for a slate of other proposals before lawmakers wind down work for the year. Likely to pass both the House and Senate, the legislation targets several common PBM tactics like spread pricing and rebates. It also includes new transparency measures, according to the text of the healthcare portion of the bill posted by Punchbowl News . The bill would require PBMs to “fully pass through 100 percent of drug rebates and discounts, excluding bona fide service fees, to the employer or health plan,” according to a summary . It also would require PBMs to provide group health plans with detailed drug spending data at least semi-annually. Another section would ban what’s known as “spread pricing” under Medicaid, which occurs when PBMs pocket the difference between the amount it reimburses a pharmacy for a prescription and the amount it charges a health plan for the drug. The Pharmaceutical Care Management Association, which lobbies for PBMs, criticized the bill in a statement Monday, saying the package “has morphed into a massive 400-page bill that includes provisions that would undermine the role that pharmacy benefit managers, PBMs, play in lowering costs and providing choices for employers in the prescription drug marketplace. Sweeping health reform policies like this should be the result of a more thoughtful and intentional approach.” The bill also requires PBMs to use pricing terms in contracts with Part D plan sponsors “transparently and consistently,” sets annual reporting requirements for PBMs on drug prices and other information to Part D plan sponsor clients, and provides those clients with “new audit rights with respect to PBMs.” Other pharma-related sections of the bill include one seeking to curb so-called “patent thickets” — a tactic made famous by AbbVie for its drug Humira — which would limit the number of patents that a reference biologic manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar. The spending bill also would reauthorize the rare pediatric priority review voucher program through 2029, and the medical countermeasure priority review voucher program through 2026.

Priority ReviewPatent Infringement

100 Deals associated with Adalimumab

External Link

KEGG	Wiki	ATC	Drug Bank
D02597	Adalimumab	L04AB04	DB00051

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pyoderma Gangrenosum	JP	AbbVie GK	27 Nov 2020
Pustular psoriasis	JP	AbbVie GK	23 Mar 2018
Behcet Syndrome	JP	AbbVie GK	17 Jun 2016
Psoriasis vulgaris	JP	AbbVie GK	17 Jun 2016
Colitis, Ulcerative	AU	AbbVie Pty Ltd.	10 Dec 2003
Hidradenitis Suppurativa	AU	AbbVie Pty Ltd.	10 Dec 2003
Non-infectious anterior uveitis	AU	AbbVie Pty Ltd.	10 Dec 2003
Psoriasis	AU	AbbVie Pty Ltd.	10 Dec 2003
Enthesitis-Related Arthritis	EU	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Enthesitis-Related Arthritis	IS	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Enthesitis-Related Arthritis	LI	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Enthesitis-Related Arthritis	NO	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Juvenile Idiopathic Arthritis	EU	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Juvenile Idiopathic Arthritis	IS	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Juvenile Idiopathic Arthritis	LI	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Juvenile Idiopathic Arthritis	NO	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Pediatric Crohn's Disease	EU	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Pediatric Crohn's Disease	IS	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Pediatric Crohn's Disease	LI	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003
Pediatric Crohn's Disease	NO	AbbVie Deutschland GmbH & Co. KG	08 Sep 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Generalized Pustular Psoriasis	Phase 3	-	AbbVie, Inc.	28 Sep 2015
Oral Ulcer	Phase 3	US	AbbVie, Inc.	01 May 2014
Oral Ulcer	Phase 3	AT	AbbVie, Inc.	01 May 2014
Oral Ulcer	Phase 3	BE	AbbVie, Inc.	01 May 2014
Oral Ulcer	Phase 3	CA	AbbVie, Inc.	01 May 2014
Oral Ulcer	Phase 3	CZ	AbbVie, Inc.	01 May 2014
Oral Ulcer	Phase 3	DK	AbbVie, Inc.	01 May 2014
Oral Ulcer	Phase 3	FR	AbbVie, Inc.	01 May 2014
Oral Ulcer	Phase 3	DE	AbbVie, Inc.	01 May 2014
Oral Ulcer	Phase 3	HU	AbbVie, Inc.	01 May 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04009668 (CTgov)	Phase 2	Nephrosis, Lipoid \| Neoplasms \| Glomerulosclerosis, Focal Segmental ... View more	7	adalimumab	iyqywkidcx(ttrdysfcin) = ttekzatssi nskfhzpads (xihateacsw, etzichvczs - hphscpeztx) View more	-	30 Oct 2024
EURETINA2024	Not Applicable	Uveitis	-	Adalimumab	ekxditeqqi(mprevnkeeq) = vyecfuzmjw lhnfasdswg (siynykppmo, 116.73) View more	-	19 Sep 2024
EURETINA2024	Not Applicable	Non-infectious anterior uveitis	-	Adalimumab	yahswjdqmk(fjasbbptwy) = Multiple Sclerosis 1 year after adalimumab use qrkomafrmf (nwqjigjbdj )	-	19 Sep 2024
NCT02451748 (CTgov)	Phase 4	Rheumatoid Arthritis	32	Lab Work (DMARD's Responder and Non-Responder)	wlyhuezzoa(gtnvsktkze) = neicyhbztt qravzvhvhs (gutjqkxlkd, hmppfmrpzg - elecyolghf) View more	-	10 Jul 2024
				Naproxen+Medrol+Hydroxychloroquine+humira+Prednisone+Lab Work+Triamcinolone+Sulfasalazine+Certolizumab pegol (CDP870, tradename Cimzia)+Methotrexate+Leflunomide (DMARD's Plus Cimzia (Certolizumab Pegol))	ehkysivsoi(mnjnzuraes) = vjglgcrula inlxvzxblt (jfhheinqtt, sxansspbfi - rkduqbhlsy) View more
EULAR2024	Not Applicable	IL-17A	135	Adalimumab (ADA)	rkjlwymypz(ezhgvuvjaz) = dpxehxkcni uasyyqldcu (gfjwjxljyd )	Positive	05 Jun 2024
				Infliximab (IFX)	rkjlwymypz(ezhgvuvjaz) = mkudyzmrha uasyyqldcu (gfjwjxljyd )
EULAR2024	Not Applicable	Arthritis, Psoriatic	-	Secukinumab	nrutvmwjma(svrbhhqaqx) = jmieuhavmk unyirodjff (gqzcnpoyok ) View more	Positive	05 Jun 2024
				Adalimumab	surltjstar(tgrhbnnwcx) = pzybevllhw jjkaoalswo (dgodypuudg ) View more
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	biologic drugs (Obese patients)	kzjzarlvrt(cttxbvkrep) = tvoamvsgdv kgzqiryvmq (rktyxswjlx ) View more	Negative	05 Jun 2024
				biologic drugs (Non-obese patients)	kzjzarlvrt(cttxbvkrep) = mwsbsmxtsu kgzqiryvmq (rktyxswjlx ) View more
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Rituximab	dcoiquwybv(fepkdixkxi) = yijluokkti umzurdwewp (xiwobhkret ) View more	-	05 Jun 2024
				Tocilizumab	dcoiquwybv(fepkdixkxi) = wrlhgupauf umzurdwewp (xiwobhkret ) View more
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Biologic and targeted synthetic DMARDs	wovleakqln(mvtqukmyhj) = bscctiepbp sbxdgwfysk (ynwyusrqjl ) View more	-	05 Jun 2024
NCT05155592 (Pubmed \| Ocul Immunol Inflamm) Manual	Phase 2	Uveitis	18	Adalimumab 20/40 mg every 2 weeks	ibqlivqshy(lthqjrjynk) = zxgzvhlpby rtgcefdvgv (nnnevubwjq ) View more	Positive	23 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis